此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated HF With Ischemic Systolic Dysfunction (FHID)

2016年1月5日 更新者:Vyacheslav Ryabov、Russian Academy of Medical Sciences

Clinical and Morphological Characteristics of Chronic Inflammation in the Myocardium in Patients With Decompensated Heart Failure With Ischemic Systolic Dysfunction

The purpose of the study is to investigate the clinical and morphological characteristics of chronic subclinical inflammation in the myocardium in patients with decompensated heart failure with ischemic systolic dysfunction.

研究概览

详细说明

Important reason for the development of chronic heart failure is a viral disease of the heart, the three phenotypes associated with: the presence of inflammation without viral agent, implying an autoimmune disease; presence of inflammation and persistent viruses; and the presence of persistent virus without signs of inflammation.

There is a group of patients with coronary heart disease, which on the background of optimal treatment is observed progression of clinical symptoms of coronary heart disease with the subsequent development of heart failure, leading to ischemic cardiomyopathy. Perhaps the reason for this is the combination of inflammatory and ischemic cardiomyopathies.

Inflammatory cardiomyopathy, involved in the pathogenesis of DCM, includes idiopathic, autoimmune and infectious subtypes. Inflammatory disease of the myocardium diagnosed by established histological, immunological and immunohistochemical criteria.

This study will include 60 patients with decompensated heart failure with ischemic left ventricular systolic dysfunction (LVEF <40%) were hospitalized not earlier than 6 months after myocardial revascularization. This group of patients will receive standard treatment, according to national guidelines RSC and ESC, to stabilize heart failure. All patients will be held PCI to exclude ischemic heart failure decompensation. Also, all patients will be performed endomyocardial biopsy as a result of immunohistochemical studies will be made on the separation of the virus and the virus-negative-positive group. After that, the group will be divided into subgroups: virus - and inflammation in the myocardium inflammation without viral antigen, viral inflammation of the presence of antigen and the group with the presence of viral antigen without any signs of inflammation in the myocardium.

The study is nonrandomized.

研究类型

介入性

注册 (预期的)

60

阶段

  • 不适用

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Tomsk、俄罗斯联邦、634012
        • 招聘中
        • Scientific and Research Institution of Cardiology of Siberian Department of RAMS
        • 首席研究员:
          • Vyacheslav Ryabov, MD, PhD
        • 接触:
    • Tomskii region
      • Tomsk、Tomskii region、俄罗斯联邦、634012
        • 招聘中
        • Research Institutite for Cardiology
        • 接触:
        • 首席研究员:
          • Vyacheslav Ryabov, MD, PhD

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 至 75年 (成人、年长者)

接受健康志愿者

不

有资格学习的性别

全部

描述

Inclusion Criteria:

  • Men and women over the age of 18 years old and weighing up to 130 kg
  • Clinical symptoms of decompensated heart failure in history
  • Heart failure decompensation requiring hospitalization for at least 3 of the following symptoms: shortness of breath, or position orthopnea, rales, peripheral edema, jugular venous pulsations, signs of stagnation in the pulmonary circulation according to the X-ray of the chest
  • Confirmed coronary heart disease with diastolic dysfunction (LVEF <40%) in history and at the time of admission
  • The term of the inclusion of patients in the study did not earlier than six months after revascularization (PCI or CABG)
  • Patients receiving medical treatment according to national guidelines RSC and ESC with individually tailored doses of drugs

Exclusion Criteria:

  • The refusal of a patient to conduct the necessary studies
  • Poor visualization of the heart when ultrasound
  • Hemodynamically significant valvular heart disease
  • Acute coronary syndrome
  • Тhrombosis of the right atrium and right ventricle
  • Condition after the operation, impeding access to the right ventricle (cava filters plication vena cava, Mustard or Senning operation on the d-transposition of the great arteries, a mechanical prosthetic tricuspid valve)
  • Severe comorbidities

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

  • 主要用途:诊断
  • 分配:不适用
  • 介入模型:单组作业
  • 屏蔽:无(打开标签)

武器和干预

参与者组/臂
干预/治疗
其他:chronic inflammation
All patients will be held PCI to exclude ischemic heart failure decompensation. Also, all patients will be performed endomyocardial biopsy.
Endomyocardial biopsy will be performed through a puncture in the femoral vein. 3-6 samples taken under the control of myocardial echocardiography or flyuroskopii. Samples of biopsy material then transmitted Pathomorphology for immunohistochemistry, light microscope.
其他名称:
  • 欧洲工商局

研究衡量的是什么?

主要结果指标

结果测量
大体时间
Incidence of inflammatory infiltrate in the myocardial tissue
大体时间:6 month after PCI or CABG
6 month after PCI or CABG

次要结果测量

结果测量
大体时间
Incidence of the virus - positive inflammatory infiltrate in the myocardial tissue
大体时间:6 month after PCI or CABG
6 month after PCI or CABG
The most frequent viral agents in myocardial tissue in this region
大体时间:6 month after PCI or CABG
6 month after PCI or CABG
Incidence of the acute myocardial infarction
大体时间:6 and 12 month after PCI or CABG
6 and 12 month after PCI or CABG
Incidence of disturbance rhythm and conduction of the heart
大体时间:6 and 12 month after PCI or CABG
6 and 12 month after PCI or CABG
Left ventricular ejection fraction (Echo)
大体时间:6 and 12 month after PCI or CABG
6 and 12 month after PCI or CABG
Еnd-diastolic volume of the left ventricle (Echo)
大体时间:6 and 12 month after PCI or CABG
6 and 12 month after PCI or CABG
Еnd-systolic volume of the left ventricle (Echo)
大体时间:6 and 12 month after PCI or CABG
6 and 12 month after PCI or CABG
Incidence of the mortality
大体时间:6 and 12 month after PCI or CABG
6 and 12 month after PCI or CABG
Incidence of the stroke
大体时间:6 and 12 month after PCI or CABG
6 and 12 month after PCI or CABG
Incidence of hospitalizations for decompensation heart failure
大体时间:6 and 12 month after PCI or CABG
6 and 12 month after PCI or CABG

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Vyacheslav Ryabov, MD, PhD、Research Institute for Cardiology

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始

2016年1月1日

初级完成 (预期的)

2018年2月1日

研究完成 (预期的)

2018年10月1日

研究注册日期

首次提交

2016年1月4日

首先提交符合 QC 标准的

2016年1月5日

首次发布 (估计)

2016年1月7日

研究记录更新

最后更新发布 (估计)

2016年1月7日

上次提交的符合 QC 标准的更新

2016年1月5日

最后验证

2016年1月1日

更多信息

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅